Login to Your Account

Astrazeneca looks to benralizumab as next-gen asthma standout

By Marie Powers
News Editor

Tuesday, September 6, 2016

Looking to mine more gold from its respiratory drug franchise, Astrazeneca plc offered up full data from the pivotal phase III trials of benralizumab at the European Respiratory Society (ERS) meeting in London.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription